{
  "metadata": {
    "company": "LAURUSLABS",
    "report_generated_on": "2025-04-28",
    "source_documents": [
      {
        "file_name": "Laurus Labs Limited Q4 FY25 Earnings Conference Call Transcript - April 24, 2025.pdf",
        "type": "Earnings Call Transcript",
        "period_covered": "Q4 FY25",
        "url": ""
      },
      {
        "file_name": "Laurus Labs Limited FY25 Results Presentation - April 24, 2025.pdf",
        "type": "Investor Presentation",
        "period_covered": "FY25",
        "url": ""
      }
    ],
    "base_currency": {
      "inr": "INR",
      "usd": "USD"
    }
  },
  "data_extraction": {
    "latest_quarter": {
      "period_label": "Q4 FY25",
      "revenue": {
        "total_inr": 1720,
        "total_usd": null,
        "cc_growth_pct": {
          "qoq": null,
          "yoy": 19
        },
        "usd_growth_pct": {
          "qoq": null,
          "yoy": null
        }
      },
      "profitability": {
        "gross_margin_pct": 54.5,
        "ebitda_inr": 477,
        "ebitda_margin_pct": 27.7,
        "ebit_inr": null,
        "ebit_margin_pct": null,
        "pat_inr": 234,
        "pat_usd": null,
        "pat_margin_pct": 13.6,
        "basic_eps_inr": 4.3
      },
      "order_book": {
        "tcv_new_deals": null,
        "pipeline_commentary": ""
      },
      "cash_flow_balance_sheet": {
        "ocf_to_pat_ratio": null,
        "fcf_to_pat_ratio": null,
        "cash_and_investments_inr": 100,
        "cash_and_investments_usd": null,
        "dso_days": null
      },
      "segment_performance": [
        {
          "segment": "CDMO - Small Molecules",
          "revenue_inr": 461,
          "growth_pct_qoq": 15
        },
        {
          "segment": "CDMO - Bio",
          "revenue_inr": 29,
          "growth_pct_qoq": -40
        },
        {
          "segment": "Generics - API",
          "revenue_inr": 686,
          "growth_pct_qoq": 29
        },
        {
          "segment": "Generics - FDF",
          "revenue_inr": 544,
          "growth_pct_qoq": 25
        }
      ],
      "geographic_performance": [],
      "headcount_metrics": {
        "total_headcount": null,
        "net_additions_yoy": null,
        "attrition_pct_ttm": null,
        "utilization_excl_trainees_pct": null
      },
      "dividend": {
        "final_dividend_per_share_inr": 0.8
      }
    },
    "current_fy": {
      "period_label": "FY25",
      "revenue": {
        "total_inr": 5554,
        "total_usd": null,
        "cc_growth_pct_yoy": 10,
        "usd_growth_pct_yoy": null
      },
      "profitability": {
        "gross_margin_pct": 55.4,
        "ebitda_inr": 1115,
        "ebitda_margin_pct": 20.1,
        "ebit_inr": null,
        "ebit_margin_pct": null,
        "pat_inr": 358,
        "pat_usd": null,
        "pat_margin_pct": 6.4,
        "basic_eps_inr": 6.6
      },
      "order_book": {
        "tcv_fy": null,
        "tcv_growth_pct_yoy": null,
        "pipeline_commentary": ""
      },
      "cash_flow_balance_sheet": {
        "ocf_to_pat_ratio": null,
        "fcf_to_pat_ratio": null,
        "cash_and_investments_inr": null,
        "cash_and_investments_usd": null,
        "dso_days": null
      },
      "segment_performance": [
        {
          "segment": "CDMO",
          "revenue_inr": 1534,
          "growth_pct_yoy": 42
        },
        {
          "segment": "Generics",
          "revenue_inr": 4020,
          "growth_pct_yoy": 2
        }
      ],
      "geographic_performance": [],
      "headcount_metrics": {
        "total_headcount": 7042,
        "net_additions_yoy": null,
        "attrition_pct_ttm": null,
        "utilization_excl_trainees_pct": null
      },
      "dividend": {
        "total_dividend_per_share_inr": null
      }
    }
  },
  "financial_analysis": {
    "performance_summary": "",
    "trend_analysis": {
      "latest_quarter": {
        "narrative": ""
      },
      "full_year": {
        "narrative": ""
      }
    },
    "segment_geographic_deep_dive": "",
    "deal_wins_pipeline_quality": "",
    "management_commentary_outlook": "",
    "comparison_to_expectations": "",
    "key_risks_headwinds": "",
    "operational_efficiency": ""
  }
}